Bristol-Myers Squibb to open up cancer treatment program to settle Merck Sharpe & Dohme lawsuit
Competition & Consumer Protection 2022-02-09 7:01 pm By Cat Fredenburgh | Melbourne
Please login to bookmark Close

Bristol-Myers Squibb has agreed to open up its subsidised treatment program for stage IV melanoma patients to individuals who have been treated with drugs made by its competitors to settle a misuse of market power lawsuit brought by rival Merck Sharpe & Dohme.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au